Allarity Therapeutics ALLR

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.06 (+5.77%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Allarity Therapeutics (ALLR)
    Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1.06

    • Market Cap

      $4.70 Million

    • Price-Earnings Ratio

      -0.14

    • Total Outstanding Shares

      4.43 Million Shares

    • Total Employees

      6

    • Dividend

      No dividend

    • IPO Date

      December 21, 2021

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      24 school st., 2nd floor, Boston, MA, 02108

    • Homepage

      https://www.allarity.com

    Historical Stock Splits

    If you bought 840,000 shares of ALLR before March 27, 2023, you'd have 1 share today.
    Execution DateSplit Amount
    September 11, 20241-for-30 (Reverse Split)
    April 9, 20241-for-20 (Reverse Split)
    June 29, 20231-for-40 (Reverse Split)
    March 27, 20231-for-35 (Reverse Split)

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-5.44 Million
    Net Cash Flow From Investing Activities, Continuing$575,000
    Net Cash Flow From Investing Activities$770,000
    Exchange Gains/Losses$-195,000
    Net Cash Flow From Financing Activities$4.87 Million
    Net Cash Flow From Financing Activities, Continuing$4.87 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Preferred Stock Dividends And Other Adjustments$562,000
    Income/Loss From Continuing Operations Before Tax$-11.97 Million
    Depreciation and Amortization$5,000
    Basic Earnings Per Share$-7.71
    Income/Loss From Continuing Operations After Tax$-11.59 Million
    Basic Average Shares$1.58 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss$-11.75 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-11.75 Million
    Other Comprehensive Income/Loss$-11.75 Million

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Equity Attributable To Noncontrolling Interest$0
    Other Current Liabilities$2.72 Million
    Noncurrent Liabilities$0
    Fixed Assets$12,000
    Equity Attributable To Parent$12.96 Million
    Current Liabilities$7.41 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALLR from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.